Lyrical Asset Management LP Makes New Investment in Icon Plc $ICLR

Lyrical Asset Management LP purchased a new position in shares of Icon Plc (NASDAQ:ICLR) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 967,961 shares of the medical research company’s stock, valued at approximately $176,382,000. Icon comprises about 2.5% of Lyrical Asset Management LP’s portfolio, making the stock its 18th largest position. Lyrical Asset Management LP owned 1.20% of Icon as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the company. Toth Financial Advisory Corp bought a new position in Icon in the 4th quarter worth about $27,000. Ameriflex Group Inc. bought a new position in Icon in the 3rd quarter worth approximately $33,000. Johnson Financial Group Inc. acquired a new stake in Icon in the 3rd quarter valued at approximately $71,000. Quadrant Capital Group LLC acquired a new stake in Icon in the 3rd quarter valued at approximately $78,000. Finally, Geneos Wealth Management Inc. raised its stake in Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 56 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Stock Performance

Shares of ICLR stock opened at $149.45 on Monday. The stock has a 50-day simple moving average of $117.51 and a 200 day simple moving average of $140.74. The stock has a market capitalization of $11.44 billion, a P/E ratio of 24.26, a P/E/G ratio of 11.81 and a beta of 1.26. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $211.00. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, May 27th. The medical research company reported $2.21 earnings per share for the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. The company had revenue of $2.11 billion during the quarter. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, sell-side analysts expect that Icon Plc will post 9.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Leerink Partners set a $145.00 price target on Icon in a research note on Thursday, May 28th. Royal Bank Of Canada upped their price objective on shares of Icon from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Friday, May 29th. DA Davidson set a $164.00 target price on shares of Icon in a research note on Monday, June 1st. Jefferies Financial Group restated a “buy” rating and set a $165.00 price target on shares of Icon in a research report on Friday, May 29th. Finally, Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the stock a “neutral” rating in a research note on Tuesday, February 17th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Icon has an average rating of “Hold” and an average target price of $156.44.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.